, Volume 83, Issue 4, pp 450-457

Multiple-Sklerose-Dokumentationssystem 3D

Purchase on Springer.com

$39.95 / €34.95 / £29.95*

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Zusammenfassung

Hintergrund

Das sich stetig vergrößernde Spektrum von Behandlungsoptionen der Multiplen Sklerose (MS) erfordert ein spezifisches Therapie- und Risikomanagement, um das individuelle Ansprechen, aber auch potenzielle Nebenwirkungen zu erfassen.

Material und Methoden

Der vorliegende Artikel stellt das neuartige computergestützte Patientenmanagementsystem Multiple-Sklerose-Dokumentationssystem 3D (MSDS 3D) vor.

Ergebnisse

MSDS 3D integriert Daten von Patienten, betreuenden Ärzten und MS-Schwestern (3 Dimensionen). Es erlaubt die Dokumentation von Vorstellungsterminen (Visiten) sowie Untersuchungsbefunden über interaktive Bildschirmoberflächen (Touchscreens). Ein spezifisches, in die aktuelle Version von MSDS 3D integriertes Modul dient der monatlichen Evaluation von Patienten unter der Therapie mit Natalizumab. Die Entwicklung einer Checkliste für Zeichen einer progressiven multifokalen Leukenzephalopathie (PML) sowie eines Natalizumab-Fragebogens könnten dazu beitragen, diese in Frühstadien gut therapierbare Erkrankung zeitnah zu erkennen.

Abstract

Background

The increasing therapeutic options for relapsing-remitting multiple sclerosis require a specific treatment and risk management to recognize the individual response as well as potential side effects. To switch from pure MS documentation to MS management by implementing a new multiple sclerosis management and documentation tool may be of importance.

Method

This article presents the novel computer-based patient management system „multiple sclerosis management system 3D“ (MSDS 3D).

Results

MSDS 3D allows documentation and visualization of visit schedules and mandatory examinations via defined study modules by integration of data input from patients, attending physicians and MS nurses. It provides forms for the documentation of patient visits as well as clinical and diagnostic findings. Information is collected via interactive touch screens. A specific module which is part of MSDS 3D’s current version allows the monthly monitoring of patients under treatment with natalizumab. A checklist covering clinical signs of progressive multifocal leukoencephalopathy (PML) and a detailed questionnaire about the handling of natalizumab in practice have additionally been added.

Discussion

The MS patient management system MSDS 3D has successfully been implemented and is currently being evaluated in a multi-centre setting. Advanced assessment of patient data may allow improvements in clinical practice and research work. The addition of a checklist and a questionnaire into the natalizumab module may support the recognition of PML during its early, treatable course.